Please try another search
Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company’s product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Name | Age | Since | Title |
---|---|---|---|
Charles L. Pope | 72 | 2010 | Executive Chairman |
Frederick W. Telling | 72 | 2010 | Independent Director |
Robert Clayton Koski | 65 | 2009 | Independent Director |
Kimberly M. Murphy | 60 | 2020 | Director |
Timothy Cooke | - | - | Member of Scientific Advisor |
Alan W. Dunton | 70 | 2011 | Independent Director |
David Zarley | - | - | Member of Scientific Advisor |
Terrence Cochrane | - | - | Member of Scientific Advisor |
John P. Gandolfo | 63 | 2023 | Independent Director |
Bruce A. Cassidy | 73 | 2023 | Independent Director |
James P. Kelly | - | 2024 | Chief Medical Officer & Member of Scientific Advisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review